“…These findings are in line with the overexpression of Akt2 and the phosphorylated form of Akt2 in other cancers and hereditary cancer syndromes, including cancers of the brain, endometrium, ovary, breast, prostate, kidney, colon, lung, thyroid, blood components, glioblastoma, head and neck, neurofibromatosis, tuberous sclerosis, von‐Hippel–Lindau disease, nevoid basal cell carcinoma syndrome, Cowden disease, Peutz‐Jeghers syndrome, familial adenomatous polyposis, and juvenile polyposis . Some studies have shown that Akt2 and p‐Akt overexpression is also associated with poor prognostic parameters of oral cancer, including increased lymph node metastasis, tumor size, and decreased survival rate …”